Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Quan Tang

Showing results (501-510 of 515) with videos related to

Pageof 52
Sort By:
JAMA Oncology|June 18, 2025
Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical TrialShan-Shan Guo, Xiao-Yun Li, Li-Ting Liu, et al.
The Lancet. Oncology|November 10, 2024
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trialSai-Lan Liu, Xiao-Yun Li, Jin-Hao Yang, et al.
The Lancet. Oncology|June 8, 2023
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trialLi-Ting Liu, Huai Liu, Ying Huang, et al.
JAMA Oncology|July 24, 2020
Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical TrialRui You, You-Ping Liu, Pei-Yu Huang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2025
[<sup>18</sup>F] Fluorodeoxyglucose positron emission tomography/computed tomography scan and liquid biopsy at 12 weeks posttreatment for surveillance of locoregionally advanced nasopharyngeal carcinomaLi-Ting Liu, Zhen-Chong Yang, Jia-Rui He, et al.
Eclinicalmedicine|November 17, 2025
Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trialYu-Chen Li, Xiao-Yun Li, Kai-Qi Lan, et al.
Journal of the National Cancer Institute|October 16, 2015
Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal CarcinomaLin-Quan Tang, Chao-Feng Li, Jing Li, et al.
BMC Medicine|November 28, 2023
Radiomic signatures reveal multiscale intratumor heterogeneity associated with tissue tolerance and survival in re-irradiated nasopharyngeal carcinoma: a multicenter studyTing Liu, Di Dong, Xun Zhao, et al.
JAMA Oncology|March 24, 2022
Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical TrialWang-Zhong Li, Xing Lv, Dan Hu, et al.
The Lancet. Oncology|March 5, 2018
Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trialLin-Quan Tang, Dong-Ping Chen, Ling Guo, et al.
Pageof 52

Showing results (501-510 of 515) with videos related to

Sort By:
Pageof 52
JAMA Oncology|June 18, 2025
Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical TrialShan-Shan Guo, Xiao-Yun Li, Li-Ting Liu, et al.
The Lancet. Oncology|November 10, 2024
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trialSai-Lan Liu, Xiao-Yun Li, Jin-Hao Yang, et al.
The Lancet. Oncology|June 8, 2023
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trialLi-Ting Liu, Huai Liu, Ying Huang, et al.
JAMA Oncology|July 24, 2020
Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical TrialRui You, You-Ping Liu, Pei-Yu Huang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2025
[<sup>18</sup>F] Fluorodeoxyglucose positron emission tomography/computed tomography scan and liquid biopsy at 12 weeks posttreatment for surveillance of locoregionally advanced nasopharyngeal carcinomaLi-Ting Liu, Zhen-Chong Yang, Jia-Rui He, et al.
Eclinicalmedicine|November 17, 2025
Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trialYu-Chen Li, Xiao-Yun Li, Kai-Qi Lan, et al.
Journal of the National Cancer Institute|October 16, 2015
Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal CarcinomaLin-Quan Tang, Chao-Feng Li, Jing Li, et al.
BMC Medicine|November 28, 2023
Radiomic signatures reveal multiscale intratumor heterogeneity associated with tissue tolerance and survival in re-irradiated nasopharyngeal carcinoma: a multicenter studyTing Liu, Di Dong, Xun Zhao, et al.
JAMA Oncology|March 24, 2022
Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical TrialWang-Zhong Li, Xing Lv, Dan Hu, et al.
The Lancet. Oncology|March 5, 2018
Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trialLin-Quan Tang, Dong-Ping Chen, Ling Guo, et al.
Pageof 52